Recently, Li Jinle, Party Secretary and Director of the Luoyang Municipal Health Commission, Li Jinle; Deputy Director Yao Nana; Office Director Li Honglei; Li Yanbing, Member of the Standing Committee of the Mengjin District Committee and Director of the Propaganda Department, Li Yanbing; Song Xianghui, Party Secretary and Director of the District Health Commission, Song Xianghui; Liu Xiaoge, Party Secretary of the Second Affiliated Hospital of Henan University of Science and Technology, Liu Xiaoge; Wang Huirui, Vice President and Academic Leader of the Hematology Department, Wang Huirui; Liu Yuhong, Director of the Pharmacy Department, Liu Yuhong; Wang Songyun, Director of the Hematology Department, Wang Songyun; Liu Xiaojing, Head Nurse of the Hematology Department, Liu Xiaojing; Wang Zesong, Key Staff of the Central Laboratory, Wang Zesong; Yan Tao, Chairman of Luoyang Meilun Group, Yan Tao; Chairman's Assistant Tan Wei; Engineering Technology Department Yang Wenbei; Xu Xuejun, Chairman of Henan Ruida Pharmaceutical Technology Co., Ltd., Xu Xuejun； Xia Junkai and other delegation members visited Shenzhen-Hong Kong Cell Valley for in-depth exchanges. Our company's Chairman and General Manager, Professor Shi Yuan Yuan; Chairman Tang Xiaomeng; Administrative Director Wei Zheng; Chairman's Assistant Fu Yuchen; Marketing Director Sun Rui; General Office Director Han Shu; Marketing Manager Fang Yixun and others warmly welcomed the delegation.

First, under the guidance of Marketing Director Sun Rui, the delegation visited the Smart Exhibition Hall. Through the honor wall, product display area, and industrial layout, the company's multiple industry certifications, technical patents, and honorary awards in the CGT field were introduced in detail. The technical advantages and application scenarios of core products were visually presented, and the company's industrial layout plan of 'rooted in Shenzhen, radiating nationwide, and connecting globally' was systematically explained.

Subsequently, during the symposium, Chairman Professor Shi Yuan Yuan comprehensively introduced the company's core advantages, from the full industrial chain layout covering 'technology R&D - large-scale production - clinical transformation' to the strategic plan centered on 'innovation-driven, compliance-led, and inclusive healthcare,' fully demonstrating the company's profound accumulation in the CGT field. He stated that China's CGT industry is currently benefiting from continuous policy dividends, especially with the promulgation of the State Council's Order No. 818, 'Regulations on the Clinical Research and Clinical Transformation Application of New Biomedical Technologies,' indicating a development trend of 'opening doors, strict supervision, and industrial focus.' With keen market insight and strong technical capabilities, the company has already taken the lead in this field. Luoyang, as an important city in the Central Plains, has a deep foundation and vast development space in the healthcare industry, offering significant potential for collaboration between the two parties in the CGT field.

The Luoyang delegation shared the city's resource advantages, policy support, and current project progress in the biopharmaceutical industry, particularly in the CGT field. Director Li Jinle mentioned that the Luoyang municipal government places high importance on the development of the biopharmaceutical industry and has introduced a series of supportive policies aimed at building a globally competitive biopharmaceutical industrial cluster. He particularly emphasized Luoyang's unique strengths in research platform construction and clinical resources, which provide a solid foundation for innovative R&D and industrial applications in the CGT field. He added that the purpose of the Luoyang delegation's visit was to leverage the advanced experience and technological advantages of Cell Valley Group in the CGT sector, jointly explore new models of government-enterprise collaboration, and promote the high-quality development of Luoyang's CGT industry.

The visit by the Luoyang delegation has established an important bridge for Cell Valley Group to expand regional cooperation in the Central Plains. Moving forward, we will continue to uphold the philosophy of open collaboration, with technological innovation as the core and industrial synergy as the link, working hand in hand with relevant institutions in Luoyang to accelerate the industrialization of CGT technologies, jointly create new regional industrial growth poles, and contribute even greater strength to the development of China's cell and gene therapy industry!